paclitaxel/edema

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

8 rezultatima

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Lung cancer is the most common cancer, accounting for 20% of cancer-related deaths worldwide. In 2015, an estimated 610,200 patients (22 per cent of cancer-related deaths) died of lung cancer. Non-small cell lung cancer ((NSCLC)) accounts for 80% to 85% of lung cancer. Most patients are locally

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Glioblastoma (GBM), the most common and most malignant primary brain tumor, represents a major medical challenge considering its extremely poor prognosis (Wen 2008). Current standard of care includes maximal surgical resection, followed by concomitant radio-chemotherapy (temozolomide - TMZ) (RT-CT)

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

The adjuvant treatment of resected pancreatic cancer is currently in flux. Many in the United States continue to use 5FU-based chemotherapy with radiation to the pancreatic bed. Some in the States, and most investigators in Europe, use a 5FU based chemotherapy-alone approach, based on the ESPAC-1

Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Each year more than 28,000 women are diagnosed with epithelial ovarian cancer (EOC). Over 70% of these women will present with advanced (stage III, IV) disease. The current treatment for newly diagnosed advanced EOC involves cytoreductive surgery followed by chemotherapy. The standard chemotherapy

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

There is an unmet clinical need for effective therapy of breast cancer that has metastasized to the brain. In this scenario, median survival is around 12 months using currently available therapeutic interventions. The majority of chemotherapy-based clinical trials have considered the presence of

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

- All patients will receive trastuzumab then be randomized into one of two arms. Arm A: Trastuzumab in combination with weekly vinorelbine and Arm B: Trastuzumab in combination with a weekly taxane-based regimen, either paclitaxel or docetaxel, chosen at the discretion of the investigator. -

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVES: - Compare the efficacy of polyglutamate paclitaxel (CT-2103) vs docetaxel as second-line therapy, in terms of duration of overall survival, in patients with progressive non-small cell lung cancer. - Compare the safety and toxicity of these regimens in these patients. - Compare the

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta znanošću

Radi na 55 jezika
Biljni lijekovi potpomognuti znanošću
Prepoznavanje bilja slikom
Interaktivna GPS karta - označite bilje na mjestu (uskoro)
Pročitajte znanstvene publikacije povezane s vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima